These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 38275149)
1. Metastatic castration resistant prostate cancer patients' experience with Radium-223 treatment in Japan. Akakura K; Uemura H; Kawakami S; Yokomizo A; Nakamura M; Nishimura K; Komori T; Ledesma DA Future Oncol; 2024 Apr; 20(12):781-798. PubMed ID: 38275149 [TBL] [Abstract][Full Text] [Related]
2. A qualitative research study in Japan investigating patients' experience with metastatic castration-resistant prostate cancer: from diagnosis to decision for Ra-223 treatment. Akakura K; Uemura H; Miyazaki K; Stroupe A; Seo C; Uzumcu A; Ledesma DA Future Oncol; 2021 Dec; 17(36):5103-5118. PubMed ID: 34664992 [TBL] [Abstract][Full Text] [Related]
3. Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial. Kitajima K; Igeta M; Kuyama J; Kawahara T; Suga T; Otani T; Sugawara S; Kono Y; Tamaki Y; Seko-Nitta A; Ishiwata Y; Ito K; Toriihara A; Watanabe S; Hosono M; Miyake H; Yamamoto S; Narita M; Daimon T; Yamakado K Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1487-1498. PubMed ID: 36539508 [TBL] [Abstract][Full Text] [Related]
4. Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy. Sraieb M; Hirmas N; Conrad R; Marinova M; Essler M; Herrmann K; Ahmadzadehfar H Medicine (Baltimore); 2020 Sep; 99(38):e22287. PubMed ID: 32957385 [TBL] [Abstract][Full Text] [Related]
5. Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223. Badrising SK; Louhanepessy RD; van der Noort V; Kieffer J; Coenen JLLM; Hamberg P; Beeker A; Wagenaar N; Lam M; Celik F; Loosveld OJL; Oostdijk A; Zuetenhorst H; de Feijter JM; Dezentjé VO; Ras-van Spijk S; Vegt E; Haanen JB; van de Poll-Franse LV; Zwart W; Bergman AM Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):248-255. PubMed ID: 34446849 [TBL] [Abstract][Full Text] [Related]
6. Administration of radium-223 and the prognosis in Japanese bone metastatic castration-resistant prostate cancer patients: A large database study. Kawahara T; Miyoshi Y; Ninomiya S; Sato M; Takeshima T; Hasumi H; Makiyama K; Uemura H Int J Urol; 2022 Sep; 29(9):1079-1084. PubMed ID: 35976620 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: A multi-institutional study. Matsumoto T; Hori Y; Shiota M; Blas L; Nakamura M; Seki N; Kuroiwa K; Yokomizo A; Morokuma F; Kiyoshima K; Eto M Int J Urol; 2023 Feb; 30(2):139-146. PubMed ID: 36305673 [TBL] [Abstract][Full Text] [Related]
8. Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer -5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life. Jiang XY; Atkinson S; Pearson R; Leaning D; Cumming S; Burns A; Azzabi A; Frew J; McMenemin R; Pedley ID Clin Oncol (R Coll Radiol); 2020 Oct; 32(10):e177-e187. PubMed ID: 32448724 [TBL] [Abstract][Full Text] [Related]
9. Review of Palliative Arays R; Ahmad Z; Howard L; Veselicky K; Kolodney J; SijinWen ; Hogan T J Nucl Med Technol; 2021 Mar; 49(1):70-74. PubMed ID: 33219158 [TBL] [Abstract][Full Text] [Related]
10. Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases. Yamamoto Y; Okuda Y; Kanaki T; Tanaka R; Nagahara A; Nakai Y; Nakayama M; Kakimoto KI; Nishimura K Int J Clin Oncol; 2021 Jan; 26(1):192-198. PubMed ID: 32875513 [TBL] [Abstract][Full Text] [Related]
11. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases. Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000 [TBL] [Abstract][Full Text] [Related]
12. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases. Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618 [TBL] [Abstract][Full Text] [Related]
13. Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. Kuppen MC; Westgeest HM; van der Doelen MJ; van den Eertwegh AJ; Coenen JL; Aben KK; van den Bergh AC; Bergman AM; den Bosch JV; Celik F; Hendriks MP; Lavalaye J; der Meer SV; Polee MB; Somford DM; van Oort IM; Uyl-de Groot CA; Gerritsen WR Future Oncol; 2020 Jul; 16(19):1371-1384. PubMed ID: 32469606 [No Abstract] [Full Text] [Related]
14. Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary. O'Sullivan JM; Abramowitz E; Sierra-Scacalossi L Future Oncol; 2023 May; 19(15):1021-1028. PubMed ID: 36942803 [TBL] [Abstract][Full Text] [Related]
15. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Smith M; Parker C; Saad F; Miller K; Tombal B; Ng QS; Boegemann M; Matveev V; Piulats JM; Zucca LE; Karyakin O; Kimura G; Matsubara N; Nahas WC; Nolè F; Rosenbaum E; Heidenreich A; Kakehi Y; Zhang A; Krissel H; Teufel M; Shen J; Wagner V; Higano C Lancet Oncol; 2019 Mar; 20(3):408-419. PubMed ID: 30738780 [TBL] [Abstract][Full Text] [Related]
16. Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer. Nilsson S Curr Oncol Rep; 2016 Feb; 18(2):14. PubMed ID: 26779616 [TBL] [Abstract][Full Text] [Related]
17. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Nilsson S; Cislo P; Sartor O; Vogelzang NJ; Coleman RE; O'Sullivan JM; Reuning-Scherer J; Shan M; Zhan L; Parker C Ann Oncol; 2016 May; 27(5):868-74. PubMed ID: 26912557 [TBL] [Abstract][Full Text] [Related]
18. Radium 223 for the treatment of metastatic castration-resistant prostate cancer. Miranda J; Viñal D; Pinto Á Arch Esp Urol; 2019 Jun; 72(5):500-507. PubMed ID: 31223127 [TBL] [Abstract][Full Text] [Related]
19. Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases. Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo Perez JM; Wagner V; Li R; Nordquist LT Ann Oncol; 2017 Oct; 28(10):2464-2471. PubMed ID: 28961839 [TBL] [Abstract][Full Text] [Related]
20. Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223. Rodriguez-Vida A; Torregrosa MD; Pinto Á; Climent MÁ; Olmos D; Carles J Clin Transl Oncol; 2018 Jun; 20(6):679-686. PubMed ID: 29098556 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]